https://scholars.lib.ntu.edu.tw/handle/123456789/628838
標題: | Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B) | 作者: | CHIH-HSIN YANG Ohe, Yuichiro Chiu, Chao-Hua Ou, Xiaoling Cantarini, Mireille Jänne, Pasi A Hartmaier, Ryan J Ahn, Myung Ju |
關鍵字: | TYROSINE KINASE INHIBITORS; OVERCOMING ACQUIRED-RESISTANCE; MESENCHYMAL TRANSITION; AZD9291; SAVOLITINIB; MECHANISMS; ERLOTINIB; THERAPY | 公開日期: | 23-六月-2022 | 出版社: | AMER ASSOC CANCER RESEARCH | 卷: | 28 | 期: | 19 | 起(迄)頁: | 4222 | 來源出版物: | Clinical cancer research : an official journal of the American Association for Cancer Research | 摘要: | MEK/ERK inhibition can overcome acquired resistance to osimertinib in preclinical models. Osimertinib [EGFR-tyrosine kinase inhibitor (TKI)] plus selumetinib (MEK1/2 inhibitor) was assessed in the global TATTON study. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628838 | ISSN: | 1078-0432 | DOI: | 10.1158/1078-0432.CCR-21-4329 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。